Carcinoembryonic Antigen: Its Role as a Marker in the Management of Cancer. A National Institutes of Health Consensus Development Conference
Authors: David M. Goldenberg, A. Munro Neville, Anne C. Carter, Vay Liang W. Go, Edward Douglas Hol-yoke, Kurt J. Isselbacher, Philip S. Schein, Morton Schwartz
Journal: Annals of Internal Medicine (1981)

Symposium1 March 1981Carcinoembryonic Antigen: Its Role as a Marker in the Management of Cancer. A National Institutes of Health Consensus Development ConferenceDavid M. Goldenberg, SC.D., M.D., [Chairman], A. Munro Neville, M.D., PH.D. [Rapporteur], Anne C. Carter, M.D., Vay Liang W. Go, M.D., Edward Douglas Hol-yoke, M.D., Kurt J. Isselbacher, M.D., Philip S. Schein, M.D., Morton Schwartz, PH.D.David M. Goldenberg, SC.D., M.D., [Chairman]Search for more papers by this author, A. Munro Neville, M.D., PH.D. [Rapporteur]Search for more papers by this author, Anne C. Carter, M.D.Search for more papers by this author, Vay Liang W. Go, M.D.Search for more papers by this author, Edward Douglas Hol-yoke, M.D.Search for more papers by this author, Kurt J. Isselbacher, M.D.Search for more papers by this author, Philip S. Schein, M.D.Search for more papers by this author, Morton Schwartz, PH.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-94-3-407 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptA consensus development conference was held 29 September to 1 October 1980, at the National Institutes of Health, to address issues concerning the role of carcinoembryonic antigen (CEA) as a marker in the management of cancer. This conference was sponsored by the National Cancer Institute, assisted by the Office for Medical Applications of Research, Office of the Director, NIH.For this conference, the members of the panel were limited to biomedical and clinical investigators actively working the field, clinically involved in patient care, and familiar with the technology under assessment. The panel met after the formal presentations and discussions to... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byElevated carcinoembryonic antigen in patients with COVID-19 pneumoniaLabel-Free Detection with the Resonant Mirror BiosensorPrognostic Significance of Serum and Tissue Carcinoembryonic Antigen in Patients with Gastric AdenocarcinomasPattern of carcinoembryonic antigen drop after laparoscopic radiofrequency ablation of liver metastasis from colorectal carcinomaDo Serum Angiogenic Growth Factors Provide Additional Information to That of Conventional Markers in Monitoring the Course of Metastatic Breast Cancer?Carcinoembryonic Antigen in the Staging and Follow-up of Patients with Colorectal CancerPrognostic value of Serum and Tumor Tissue CA 72-4 Content in Gastric CancerCan postoperative surveillance with serial CEA immunoscintigraphy detect resectable rectal cancer recurrence and potentially improve tumor-free survival?11Dr Goldenberg is a member of the board of Immunomedics and a shareholder. Immunomedics markets CEA-Scan (arcitumomab).Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases?A Predictive Value of Carcinoembryonic Antigen in Draining Venous Blood for Colorectal Cancer Patients with Postoperative Hematogenous MetastasesQuantitative analysis of CEA expression in colorectal adenocarcinoma and serum: Lack of correlationPre-operative circulating carcinoembryonal antigen in primary breast cancer: review of the literature and personal experience on 150 casesElevated carcinoembryonic antigen levels correlating with disease recurrence in a patient with adenoid cystic carcinomaCA 72-4 Serum Marker–A New Tool in the Management of Carcinoma PatientsBiologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, part ITAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancerSurveillance After Curative Resection of Colorectal Cancer: Individualizing Follow-UpComparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic carcinomaBronchogenic Carcinoma: Immunologic AspectsEvaluation of the Behavior of Carcinoembryonic Antigen in Cirrhotic PatientsThe Role of Serum Carcinoembryonic Antigen (CEA) in the Management of Patients with Colorectal Carcinoma: The Experience of the Istituto Tumori of MilanCancer Imaging with CEA Antibodies: Historical and Current PerspectivesCarcinoembryonic antigen levels of peripheral and draining venous blood in patients with colorectal cancer. Correlation with survivalCarcinoembryonic antigen and carbohydrate 19-9 antigen as markers for colorectal carcinoma in children and adolescentsAnalysis of Cytosol CA15-3, Carcinoembryonic Antigen, Estrogen and Progesterone Receptors in Breast Cancer TissuesCarcinoembryonic AntigenEpitope Mapping of the Nonspecific Cross-Reacting Antigen Using Various Related Recombinant Proteins Expressed in Chinese Hamster Ovary Cells and Eight Distinct Monoclonal AntibodiesTumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A lingitudinal studyMonoclonal antibodies in the management of carcinoma patientsImmunological and Biochemical Characterization of the Nonspecific Cross-Reacting Antigen Epitopes Using Twenty-three Monoclonal AntibodiesColorectal cancer patients with high risk of hematogenous metastasis: Correlation with CEA levels in peripheral and draining venous blood during the period of operationCEA in tumors of other than colorectal originSecond-look surgery for recurrent colorectal carcinoma: Is it worthwhile?A Review of the Role of Established Tumour MarkersDiagnostic significance of the tumour markers CEA, CA 15–3 and CA 125 in malignant effusions in breast cancerUpdate on colorectal cancerPresent status of serum markersCarcinoembryonic antigen and carbohydrate antigen 19-9 levels of peripheral and draining venous blood in colorectal cancer patients correlation with histopathologic and immunohistochemical variablesUsefulness of carcinoembryonic antigen measurement in feces of patients with colorectal cancerComparing predictive decision rules in postoperative CEA monitoringClinical Utility of Oncofetal and Proteins and Hormones as Tumor MarkersCarcinoembryonic AntigenROBERT H. FLETCHER, M.D., M.Sc.Carcinoembryonic Antigen and Its Utility in the Diagnosis of Colonic AdenocarcinomaTumor markers: Value and limitations in the management of cancer patientsHypothesis testing in the polychotomous logistic model with an application to detecting gastrointestinal cancerThe Biology of Human Colon Tumor Cells in CultureBiochemical markers in gastrointestinal malignanciesAntimarker antibodies for the external imaging of gastrointestinal cancerClinical perspective of human colorectal cancer metastasisNational Cancer Institute Serum Immunodiagnostic Bank at Mayo Clinic — 10 Years ExperienceBiochemical Monitoring of CancerAllergy and Immunology: An Annotated Bibliography of Recent Literature References to Journal Articles and Other PapersALLERGY AND IMMUNOLOGY COMMITTEEGastrointestinal Problems in the ElderlyDiagnostic Value of HLA-B27 Testing in Ankylosing Spondylitis and Reiter's SyndromeMUHAMMAD A. KHAN, M.D., MOHAMMAD K. KHAN, Ph.D.Consensus Statements 1 March 1981Volume 94, Issue 3Page: 407-409KeywordsCarcinoembryonic antigenPatients ePublished: 1 December 2008 Issue Published: 1 March 1981 PDF downloadLoading ...